OP0216 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS): a randomised, placebo-controlled, phase 3 trial

Abstract

BackgroundTofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA).ObjectivesTo assess the efficacy and safety of tofacitinib vs placebo (PBO) in patients (pts) with active...